| Medlmmune, LLC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135023 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 05-31-2012 |
| 20120027797 | Preservation of Bioactive Materials by Freeze Dried Foam - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 02-02-2012 |
| 20110287022 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders. | 11-24-2011 |
| 20110243996 | Spray freeze dry of compositions for intranasal administration - This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration. | 10-06-2011 |
| 20110243929 | ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder. | 10-06-2011 |
| 20110033378 | Cysteine Engineered Antibodies For Site-Specific Conjugation - Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided. | 02-10-2011 |
| 20110008329 | Methods of Treating RSV Infections And Related Conditions - The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient. | 01-13-2011 |
| 20100330162 | Spray freeze dry of compositions for pulmonary adminstration - This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles. | 12-30-2010 |
| 20100278929 | ANTIBODY FORMULATIONS HAVING OPTIMIZED AGGREGATION AND FRAGMENTATION PROFILES - The present invention provides methods of optimizing the production and purification of antibody formulations that immunospecifically bind to antigens of interest and are suitable for parenteral administration to a subject, which formulations exhibit increased stability due to reduced degradation and aggregation of the antibody component on long term storage. Such methods provide formulations that offer multiple advantages over formulations produced by non-optimized methods including less stringent or more readily available transportation/storage conditions, and less frequent dosing or smaller dosage amounts in the therapeutic, prophylactic and diagnostic use of such formulations. The invention further provides methods of utilizing the formulations of the present invention. | 11-04-2010 |
| 20100196388 | TARGETED BINDING AGENTS DIRECTED TO SONIC HEDGEHOG HOMOLOG AND USES THEREOF - The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics. | 08-05-2010 |
| 20100196385 | TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF 524 - The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics. | 08-05-2010 |
| 20090277254 | METHODS OF IMPROVING PACKED-BED CHROMATOGRAPHY PERFORMANCE - The invention provides methods of improving packed bed chromatography performance. | 11-12-2009 |
| 20090220527 | AFFINITY OPTIMIZED EPHA2 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy. | 09-03-2009 |
| 20090208532 | Methods Of Producing Influenza Vaccine Compositions - Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided. | 08-20-2009 |
| 20090186038 | Methods of Preventing or Treating Respiratory Conditions - The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits. | 07-23-2009 |
| 20090175898 | Influenza Hemagglutinin And Neuraminidase Variants - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 07-09-2009 |
| 20080279851 | ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder. | 11-13-2008 |
